Answers are grounded in this paper and cite their sources.
In recent years, several groups have reported a variety of strategies for developing biological pacemakers whose ultimate function would be to supplement/replace electronic pacemakers. Strategies have included gene therapy using naked plasmids or viral vectors and cell therapy for which both adult human mesenchymal stem cells (hMSCs) and human embryonic stem cells have been employed. This article reviews the various approaches and summarizes our own research in which the pacemaker gene, HCN2, is administered via viral vector or in an hMSC platform to produce pacemaker function in the intact canine heart.
No takes yet. Share an insight, caveat, or question.
Rosen et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: